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1. Introduction 
Since ancient times, food has been considered essential and indispensable to human life. 
Numerous studies clearly show that an individual’s quality of life is linked to daily diet and  
lifestyle (Moura, 2005).  
Interest in the role of probiotics for human health began as early as 1908 when Metchnikoff 
associated the intake of fermented milk with prolonged life (Lourens-Hattingh and Vilijoen, 
2001b). However, the relationship between intestinal microbiota and good health and 
nutrition has only recently been investigated. Therefore, it was not until the 1960’s that 
health benefit claims began appearing on foods labels.  
In recent years, there has been an increasing interest in probiotic foods, which has 
stimulated innovation and fueled the development of new products around the world. 
Probiotic bacteria have increasingly been incorporated into foods in order to improve gut 
health by maintaining the microbial gastrointestinal balance. The most popular probiotic 
foods are produced in the dairy industry because fermented dairy products have been 
shown to be the most efficient delivery vehicle for live probiotics to date.  
In this chapter, we will discuss the application of probiotic microorganisms in fermented 
dairy products, particularly cheeses. In addition, we will also discuss the benefits of 
probiotic fermented foods on human health. 
2. Probiotic concepts 
The word “probiotic” comes from Greek and means “for life” (Fuller, 1989). Over the years, 
the term “probiotic” has been given several definitions. ”Probiotic” is used to refer to 
cultures of live microorganisms which, when administered to humans or animals, improve 
properties of indigenous microbiota (Margoles and Garcia, 2003). In the food industry, the 
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term is described as “live microbial food ingredients that are beneficial to health” (Clancy, 
2003).  
It is important to mention that for a microorganism to be considered probiotic, (Figure 1), it 
must survive passage through the stomach and maintain its viability and metabolic activity 
in the intestine (Hyun and Shin, 1998). Native inhabitants of the human or animal 
gastrointestinal tract, such as lactobacilli and bifidobacteria, are considered to be probiotic, 
but often display low stress tolerance, which reduces their viability in probiotic applications. 
Microorganisms traditionally grown in fermented foods, such as lactic acid bacteria, 
propionibacteria and yeasts, are also considered for these applications.. 
 
Figure 1. Schematic representation of gastrointestinal tract 
It is essential that commercialized probiotic products which make health claims meet the 
minimum criterion of one million viable probiotic cells per milliliter of product at the 
expiration date. Accordingly, the minimum dosage of probiotic cells per day for any 
beneficial effect on the consumer is considered to be 108–109 probiotic CFU ml-1 or CFU g-1, 
which corresponds to an intake of 100 g product containing 106–107  CFU ml-1 or CFU g-1 
per day (Lorens-Hattingh and Viljoen, 2001a). 
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2.1. Selection of probiotic microorganisms 
The human intestinal tract constitutes a complex ecosystem of microorganisms. The 
bacterial population in the large intestine is very high and can reach maximum counts of 
1012 CFU g-1. In the small intestine, the bacterial content is considerably lower at only 104–108 
CFU g-1. In the stomach only 101-102 CFU g-1 are found due to the low pH of the environment 
(Lorens-Hattingh and Viljoen, 2001b). 
It is known that microbiota in the human intestine changes during human development. The 
intestine of newborn babies is fully sterile, however immediately after birth, colonization of 
many kinds of bacteria begins. On the first and second days after birth, coliforms, 
enterococci, clostridia and lactobacilli have been shown to be present present in infants’ 
feces. Within three to four days, bifidobacteria begins colonization and becomes 
predominant around the fifth day. Simultaneously, coliform counts decrease. Breast-fed 
babies show 1 log-count more of bifidobacteria in feces than bottle-fed babies. 
Enterobacteriaceae, streptococci, and other putrefactive bacteria counts are higher in bottle-
fed babies, suggesting that breast-fed babies are more resistant to gastrointestinal infections 
than the bottle-fed infants (Lorens-Hattingh and Viljoen, 2001b). 
In addition to the microbiota changes that occur during human aging, the microbiota in the 
gastrointestinal system can also change because of the food and health conditions of an 
individual. For example, use of antibiotics can damage the equilibrium of intestinal 
microbiota, reducing counts of bifidobacteria and lactobacilli and increasing clostridia. The 
ensuing imbalance can cause diarrhea in elderly and immunocompromised people. 
To help improve the balance of intestinal microbiota, probiotic microorganisms can be 
added to the human diet in order to stimulate the growth of preferred microorganisms, 
crowd out potentially harmful bacteria, and reinforce the body’s natural defense 
mechanisms.  
The selection of probiotic microorganisms is based on safety, functional and technological 
aspects, as reported by (Saarela et al., 2000). These are summarized in Figure 2. 
Certain probiotic bacteria have been extensively studied and are already on the market, as 
shown in Table 1. 
Before probiotic strains can be delivered to consumers, they must first be able to be 
manufactured under industrial conditions. They must then survive and retain their 
functionality during storage as frozen or freeze-dried cultures, as well as in the food 
products into which they are finally formulated. Moreover, they must be able to be 
incorporated into foods without producing off-flavors or textures (Saarela et al., 2000). 
Functional food requirements must take into consideration the following aspects in relation 
to the probiotics: The preparation should remain viable for large-scale production; it should 
remain stable and viable during storage and use; it should be able to survive in the intestinal 
ecosystem (Prado et al., 2008). 
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Figure 2. Theoretical basis for selection of probiotic microorganism selection (adapted from Saarela et 
al., 2000). 
 
Strains Origin 
Lactobacillus casei Shirota Yakult, Japan 
Lactobacillus reuteri MM53 BioGaia, Sweden 
Bifidobacterium lactis HN019 Danisco, France 
Lactobacillus rhamnosus GG Valio, Finland 
Lactobacillus acidophilus NCFM Nestle, Switzerland 
Lactobacillus casei DN-173 010 Danone, France 
Lactobacillus casei CRl-431 Chr. Hansen, USA 
Bifidobacterium animalis BB12 Chr. Hansen, Denmark 
Bifidobacterium animalis DN173010 Danone, France 
Source: Prado et al., 2008 
Table 1. Probiotic bacteria marketed worldwide 
3. Beneficial effects of probiotics 
The role of balanced nutrition for health maintenance has attracted the attention of the 
scientific community, which in turn has produced numerous studies in order to prove the 
performance of certain foods in reducing the risk of Some diseases. There has also been 
Probiotic strain 
characteristics 
Human 
origin
Acid and salt 
bile stability 
Adhrence to human 
intestinal cells 
Survival in the human 
intestinal tract 
Production of 
antimicrobial substances 
Antagonism against 
pathogenic bacteria 
Safety in food and 
clinical use 
Clinically validated 
and documented 
health effects 
 
Probiotics in Dairy Fermented Products 133 
considerable growing interest in encouraging research into new natural components 
(Thamer and Penna, 2006). 
In a healthy host, a balance exists among members of the gut microbiota, such that potential 
pathogenic and non-pathogenic organisms can be found in apparent harmony. In the case of 
bacterial infection, this balance can become disturbed, leading to often dramatic changes in 
the composition. 
For most bacterial infections, nonspecific antibiotics are used, killing both non-pathogenic 
members of gut microbiota as well as pathogenic members. This can lead to a substantial delay 
in the restoration of healthy gut microbiota (Reid et al, 2011). The restoration of the gut 
microbiota balance is believed to be important because maintaining a healthy and balanced 
gut microbiota throughout life is thought to help preserve health and favor longevity. 
The most comprehensive analysis of human microbiota to date examined 27 distinct sites in 
the body and revealed the presence of 22 bacterial phyla, with most sequences (92.3%) 
related to just four phyla: Actinobacteria (36.6%), Firmicutes (34.3%), Proteobacteria (11.9%) 
and Bacteroidetes (9.5%) (Costelo, 2008). 
The metabolic capacity of gut bacteria is extremely diverse. This diversity is influenced by 
the large number of bacterial genera and species. Lactic acid species are present, as well as 
peptide-degrading bacteria, amino acids, and other methanogenic bacteria components of 
the gut microbiota which grow with the intermediate products of fermentation such as 
hydrogen, lactate, succinate and ethanol (Topping and Clifton, 2001). 
In host’s diet residue (matter undigested by its digestive system including resistant starch, 
fibers, proteins and peptides) substrates for primary fermentation can be found. Other 
important available substrates derive from mucin glycoproteins, exfoliated epithelial cells 
and pancreatic Secretions (MacFarlane et al., 1992). 
Hydrolysis and carbohydrate metabolism in the large intestine is influenced by a variety of 
physical, chemical, biological and environmental parameters. Probably the nature and 
quantity of available substrate that has greater meaning, making the diet easier and the 
main mechanism by which to influence the profile of fermentation. Other factors affecting 
the colonization and growth of bacteria in the intestine are intestinal pH, which inhibits the 
production of metabolites (acids and peroxides) and specific inhibitory substances 
(bacteriocins), bile salts and molecules and cells which constitute the immune system 
(Rastall et al., 2000) . 
Knowledge of intestinal gut microbiota and their interactions led to the development of food 
strategies aimed at the stimulation and maintenance of normal bacteria present in the gut 
(Gibson and Fuller, 2000). 
According to Wohlgemuth (2010), strategies for studying mechanisms of probiotic action 
involve in-vitro models, or conventional or gnotobiotic animal models, plus development of 
a simplified human intestinal gut microbiota. Wohlgemuth’s article proposes certain 
requirements that a model should ideally fulfill: 
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 Selected bacterial species should represent numerically dominant organisms of the 
human gut microbiota. 
 By and large, the metabolic activity of this community should mimic that of normal 
human gut microbiota. 
 The genome sequence of all members of the microbial community should be known. 
 The members of this consortium should form a stable community in rodents. It should 
be possible to maintain this community under gnotobiotic conditions from generation 
to generation. 
 The composition of the microbial community should be modifiable when required.  
It is possible to increase the number of health-promoting microorganisms in gut microbiota 
through the introduction of probiotics in the diet. The probiotics will selectively modify the 
composition of the gut microbiota, providing the probiotic microorganisms demonstrate a 
competitive advantage over other bacteria in the ecosystem (Crittenden, 1999). Probiotic 
therapeutic properties are listed in Table 2.  
 
Probiotic therapeutic properties 
Influence on host gut microbiota and pathogenic bacteria 
Improvement of specific enzymatic activities 
Production of antibacterial substances 
Competitive exclusion of pathogenic bacteria 
Induction of defensin production 
Improvement of intestinal barrier function 
Modulation of host immune functions 
Modulation of intestinal carcinogenesis 
Modulation of cholesterol uptake 
Wohlgemuth et al. (2010); Reddy and Rivenson (1993); Chen et al. (1984); Zhu et al., Cancer letters (2011);  
Jones et al., Br J Nutr (2012) 
Table 2. Therapeutic Properties of Probiotics   
There is a growing body of evidence that ingested beneficial bacteria, called probiotics, can 
beneficially modulate chronic intestinal inflammation, diarrhea, constipation, vaginitis, 
irritable bowel syndrome, atopic dermatis, food allergies and liver disease (Wallace et al., 
2011, Nutrition reviews). 
Probably the most promising area is the alleviation of symptoms linked to inflammatory 
bowel diseases (IBD), a growing health concern. As an example, the probiotic preparation 
VSL#3 induced remission in children (n=18) with mild to moderate ulcerative colitis (UC) 
(Huynh et al., 2009, Inflamm. Bowel Dis.) Accordingly, VSL#3 was tested in a 1-year, 
placebo-controlled, double-blind clinical study on UC children (n=29). Remission was 
achieved in 36.4% of children receiving IBD therapy and placebo, but in 92.8% of children 
receiving IBD therapy and VSL#3 (Milele et al., 2009, Am J Gastroeterol.) Similar promising 
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results were obtained with the probiotic Escherichia coli Nissle 1917 strain (Kruis et al., 2004, 
Gut ; Do et al., Ann Pharmacother, 2010). However, a review of available data indicates that 
more clinical studies are needed to confirm the beneficial effects of these products in UC and 
in inactive pouch patients (Jonkers et al., 2012, Drugs). This review also states that there is 
no evidence to support the use of probiotics in Crohn’s disease. 
Other studies confirm these findings. Miele et al. (2009) reported that all of 29 patients 
studied responded to inflammatory bowel disease therapy. Remission was achieved in 
92.8% of patients treated with mixed probiotics and 36.4% of patients treated with placebo. 
Overall, 21.4 % patients treated with a mix of probiotics and 73.3 % patients treated with 
placebo relapsed within 1 year of follow-up. 
Urinary tract infections (UTIs) are a common and frequently recurrent infection among 
women. Depletion of vaginal lactobacilli is associated with UTI risk, which suggests that 
repletion of the bacteria may be beneficial. Young women with a history of recurrent UTI 
were randomized to receive either a probiotic or placebo daily. Recurrent UTI occurred in 
15% of women receiving probiotic compared with 27% of women receiving placebo  
(Stapleton et al., 2011). 
Probiotics have considerable potential for preventive and therapeutic applications in 
gastrointestinal disorders. However, it is important to note that many probiotic health 
claims have not yet been substantiated through experimental evidence. In addition, the 
efficacy demonstrated for a single given bacterial strain cannot be extrapolated to other 
probiotic organisms. Moreover, the mechanisms underlying probiotic action have not yet 
been fully elucidated. A better understanding of these mechanisms will be able to shed light 
on the disparate clinical data and provide new tools to help the prevention or treatment of 
health disorders (Wohlgemuth et al., 2010; Yan et al., 2011). 
4. Application of probiotic bacteria in dairy foods 
There is evidence that food matrices play an important role in the beneficial health effects of 
probiotics on the host (Espirito Santo et al., 2011). 
Fermented foods, particularly dairy foods, are commonly used as probiotic carriers. 
Fermented beverages provide an important contribution to the human diet in many 
countries because fermentation is an inexpensive technology which preserves food, 
improves its nutritional value and enhances its sensory properties (Gadaga et al., 1999). 
However, the increasing demand for new probiotic products has encouraged the 
development of other matrices to deliver probiotics, such as ice cream, infant milk power 
and fruit juice. 
Davidson et al. (2000) evaluated the viability of probiotic strains in low-fat ice cream. They 
used cultures containing Streptococcus salivarius ssp. thermophilus and Lactobacillus delbrueckii 
ssp. Bulgaricus, Bifidobacterium longum and Lactobacillus acidophilus, and verified that culture 
bacteria did not decrease in the yogurt during frozen storage. Also, the presence of probiotic 
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bacteria did not alter the sensory characteristics of the ice cream. The ice cream matrix may 
offer a good vehicle for probiotic cultures due to its composition, which includes milk 
proteins, fat and lactose, as well as other compounds. Moreover, its frozen state contributes 
to its efficiency. However, a probiotic ice cream product should have relatively high pH 
values –5.5 to 6.5, in order to favor an increased survival of lactic cultures during storage. 
The lower acidity also results in increased consumer acceptance, especially among 
consumers who prefer milder Products. (Cruz et al., 2009b). 
Growth of a probiotic yeast, Saccharomyces boulardii, in association with the bio-yogurt 
microflora, which is done by incorporating the yeast into commercial bio-yogurt, has been 
suggested as a way to stimulate growth of probiotic organisms and to assure their survival 
during storage. Lorens-Hattingh and Viljoen (2001a) studied the ability of probiotic yeast to 
grow and survive in dairy products, namely bio-yogurt, UHT yogurt and UHT milk. S. 
boulardii was incorporated into these dairy products and stored at 4 ºC over a 4-week period. 
It was observed that the probiotic yeast species, S. boulardii, had the ability to grow in bio-
yogurt and reach maximum counts exceeding 107 CFU g-1. The number of yeast populations 
was substantially higher in the fruit-based yogurt, mainly due to the presence of sucrose 
and fructose derived from the fruit. Despite the inability of S. boulardii to utilize lactose, the 
yeast species utilized available organic acids, galactose and glucose derived from bacterial 
metabolism of the milk sugar lactose present in the dairy products. 
The viability of strains of L. acidophilus and Bifidobacterium animalis ssp. lactis in stirred 
yoghurts with fruit preparations of mango, mixed berry, passion fruit and strawberry was 
evaluated during shelf-life (Godward et al., 2000; Kailasapathy et al., 2008). The authors 
observed that regardless of concentrations, the addition of any of the fruit preparations had 
no effect on the counts of the two probiotics tested. 
Fermented milks supplemented with lemon and orange fibers increased the counts of L. 
acidophilus and L. casei during cold storage compared to the control set. This was not the case 
for B. bifidum, possibly owing to the well-known sensitivity of bifidobacteria species to an 
acidic environment (Sendra et al., 2008). 
5. Probiotic cheeses 
Probiotic foods are currently primarily found in fermented milk drinks and yogurt, both of 
which have limited shelf life compared to cheeses. Incorporation of probiotic cultures in 
cheeses offers the potential not only to improve health but also product quality. It also opens 
the way to  increasing the range of probiotic products on the market. The manufacture of 
most cheeses involves combining four ingredients: milk, rennet, microorganisms and salt 
These are processed using a number of common steps such as gel formation, whey 
expulsion, acid production and salt addition. Variations in ingredient blends and 
subsequent processing have led to the evolution of all cheese varieties. 
Cheeses are dairy products which have a strong potential for delivering probiotic 
microorganisms into the human intestine, due to their specific chemical and physical 
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characteristics. Cheeses have higher pH levels, lower titratable acidity, higher buffering 
capacity, more solid consistency, relatively higher fat content, higher nutrient availability 
and lower oxygen content than yogurts. These qualities protect probiotic bacteria during 
storage and passage through the gastrointestinal tract (Karimi et al., 2011; Ong et al., 
2006).  
As mentioned above, the physicochemical properties of food influence probiotic bacteria 
survival in the digestive tract, due to the low pH in the stomach, typically between 2.5 and 
3.5 (Holzapfel et al., 1998), and the anti-microbial activity of pepsin that serve as effective 
barriers against the entrance of bacteria into the intestinal tract. Values of pH between 1 and 
5 are commonly employed in determining the in vitro acid tolerance of Lactobacillus and 
Bifidobacterium spp. (Charteris et al., 1998). Bile salt concentrations between 0.15% and 0.3% 
have been recommended as appropriate for selection of probiotic bacteria for human 
consumption (Yang and Adams, 2004).  
A variety of microorganisms, typically food-grade lactic acid bacteria (LAB), have been 
evaluated for their probiotic potential and have been applied as adjunct cultures in various 
food products or therapeutic preparations (Rodgers, 2008). Lactobacillus and Bifidobacterium 
species may be found in many foods; some are frequently regarded as probiotics due to 
their capacity to improve certain biological functions in the host. Complex interactions occur 
among resident microbiota, epithelial and immune cells and probiotics. These interactions 
play a major role in the development and maintenance of the beneficial activities for healthy 
humans (Medici el al., 2004).  
According to Karimi et al. (2012), recommendations for the minimum viable counts of each 
probiotic strain in gram or millilitre of probiotic products vary when it comes to providing 
health benefits related to probiotic organisms. For example, the minimum viable levels of 
105 cfu g-1 have been recommended (Shah, 1995); while 106 cfu g-1 (Karimi and Amiri-Rigi, 
2010; Talwalkar and Kailasapathy, 2004) and 107 cfu g-1 (Samona and Robinson, 1994) have 
been suggested for probiotics in different products. However, populations of 106-107 CFU/g 
in the final product have been shown to be more acceptable as efficient levels of probiotic 
cultures in processed foods (Talwalkar, Miller, Kailasapathy and Nguyen, 2004), with 
numbers attaining 108 - 109 CFU when provided by a daily consumption of 100 g or 100 mL 
of probiotic food, and hence benefiting human health (Jayamanne & Adams, 2006). It is 
important to emphasize that the incorporation of probiotic cultures into cheeses would 
produce functional foods only if the cultures remained viable in recommended numbers 
during maturation and shelf life of the products. 
One of the preconditions for a bacterial strain to be called probiotic is the strain’s ability to 
survive in the gastrointestinal environment, although the importance of viability for the 
beneficial effects of probiotics has not been well defined since inactivated and dead cells can 
also have immunological and health-promoting effects (Ghadimi et al., 2008; Lopez et al., 
2008). Moreover, there are significant technological challenges associated with the 
introduction and maintenance of high numbers of probiotic microorganisms in foods that 
depend on the form of the probiotic inoculant, and with the viability and maintenance of 
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probiotic characteristics in the food product up to the time of consumption. Spray drying 
has been used as a preservation method for microbial cultures. Gardiner et al. (2002) 
produced spray-dried probiotic milk powder containing the probiotic Lactobacillus paracasei 
NFBC 338. The powder contained 1 x 109 CFU.g-1 L. paracasei which was used as adjunct 
inoculums during probiotic Cheddar cheese manufacture. After three months of ripening, 
the count was 7.7 x 107 CFU.g-1, without any adverse effects on the cheese. The researchers’ 
data shows that probiotic spray-dried powder may be a useful means for adding probiotic 
strains to dairy products.  
In order to use probiotic bacteria in the manufacture of cheese products, the process may 
have to be modified and adapted to the requirements of the strains employed. Overall, 
probiotic strains should be technologically compatible with the food manufacturing 
process involved. With regard to the development of probiotic cheeses, this means that 
such strains should be cultivable to high cell density for inoculation into the cheese vat, or 
that the strains are capable of proliferating during the manufacturing and/or ripening 
process (Ross et al., 2002). In general, a probiotic cheese should have the same attributes 
as a conventional cheese: the incorporation of probiotic bacteria should not imply a loss of 
quality of the product. In this context, the level of proteolysis and lipolysis must be the 
same or even better than for cheese which does not have functional food appeal (Cruz et 
al., 2009a). 
Proteolysis plays a critical role in determining typical sensory characteristics and represents 
a significant quality indicator for certain cheeses. Proteolysis is caused by enzymes found in 
milk (plasmin), rennet (pepsin and chymosin) and microbial enzymes released by starter 
cultures. The activities of these enzymes hydrolyze the fractions of caseins, which leads to 
the formation of peptides. These peptides may be further hydrolyzed with proteolytic 
enzymes originating from microbiota such as starter bacteria, non-starter lactic acid bacteria 
(NSLAB) and probiotic adjuncts to the cheeses, into smaller peptides and free amino acids, 
which are important for flavor development in some cheeses (Ong et al., 2007; Cliffe et al., 
1993; Lynch et al., 1999). 
Three batches of Cheddar cheeses (Batch 1, with only starter lactococci; Batch 2, with 
lactococci and Lactobacillus acidophilus 4962, Lb. casei 279, Bifidobacterium longum 1941; Batch 
3, with lactococci and Lb. acidophilus LAFTIs L10, Lb. paracasei LAFTI L26, B. lactis LAFTI 
B94) were manufactured in triplicate to study the survival and influence of probiotic 
bacteria on proteolytic patterns and production of organic acid during a ripening period of 6 
months at 4 ºC. All probiotic adjuncts survived the manufacturing process and maintained 
their viability of 7.5 log10 cfu g-1 at the end of the ripening term. The number of lactococci 
decreased by one to two log cycles, but their counts were not significantly different (P> 
0.05) in either the control or the probiotic cheeses. No significant differences were 
observed in composition (fat, protein, moisture, salt content), although acetic acid 
concentration was higher in the probiotic cheeses. Proteolysis assessment during ripening 
showed no significant differences (P> 0.05) in the level of water-soluble nitrogen (primary 
proteolysis), but the levels of secondary proteolysis indicated by the concentration of free 
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amino acids were significantly higher (P> 0.05) in probiotic cheeses. These data thus 
suggested that Cheddar cheese is an effective vehicle for the delivery of probiotic 
organisms (Ong et al., 2006). 
Phillips et al. (2006) have also studied probiotic Cheddar cheese. They manufactured six 
batches of Cheddar cheese containing different combinations of commercially-available 
probiotic cultures. Duplicate cheeses contained organisms from each supplier, 
Bifidobacterium spp., Lactobacillus acidophilus and either Lactobacillus casei, Lactobacillus 
paracasei, or Lactobacillus rhamnosus. Using selective media, the different strains were 
assessed for viability during Cheddar cheese maturation over 32 weeks. Bifidobacterium sp. 
remained at high numbers with the three strains present in cheese at 4×107, 1.4×108, and 
5×108 CFU/g respectively after 32 weeks. Similarly, the L. casei (2×107 CFU/g), L. paracasei 
(1.6×107 CFU/g), and L. rhamnosus (9×108 CFU/g) strains survived well. However, the L. 
acidophilus strains performed poorly. Both decreased in a similar manner and were recorded 
at 3.6×103 CFU/g and 4.9×103 CFU/g after 32 weeks. 
Numerous scientific papers have been published on the development of fresh cheeses 
containing recognized and potentially probiotic cultures. They have described suitable 
viable counts as well as a positive influence on texture and sensorial properties of the 
cheeses. Cottage cheese in particular shows an adequate profile for the incorporation of 
probiotic cells and/or prebiotic substances. In addition, cottage cheese is a healthy 
alternative to many other cheeses by virtue of its low fat content. 
Araújo et al. (2010) developed a symbiotic cottage cheese containing Lactobacillus 
delbrueckii UFV H2b20 and inulin, and evaluated the survival of this bacterium when the 
cheese was exposed to conditions simulating those found in the gastro-intestinal tract. 
Throughout the entire storage period of the cheese, the probiotic cell counts were higher 
than recommended levels for probiotic products. The probiotic bacterium exhibited 
satisfactory resistance to low pH values and to high concentrations of bile salts. The 
addition of probiotic cells and inulin generated no alterations in the physicochemical 
characteristics of cheese. By allowing the viable microorganism has characteristics 
desirable for incorporation of a probiotic strain. Probiotic cells could be added to the 
dressing, creamy liquid that surrounds the granules of cheese because after this step there 
is not exposition at high temperature. 
Although cottage cheese is well adapted to the health requirements of modern populations, 
its consumption has been in decline over the past few years. By developing new production 
processes, cottage cheese, apart from carrying the nutritional qualities of milk, may also 
furnish consumers with a source of lactic acid bacteria, probiotic microorganisms and 
prebiotics. The lactic acid bacteria perform more critical functions in cottage cheese than just 
producing lactic acid. They also aid the manufacture process and increase the final 
rheological and sensorial qualities of the cheese. Controlling of the fermentation process 
with lactic acid bacteria allows for the enhancement of the sensorial quality of the cheese 
and could hence play a crucial role in increasing consumption of cottage cheese. 
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Souza, et al. (2008) and Souza and Saad (2009) studied the manufacture of Minas fresh 
cheese supplemented solely with the probiotic strain of L. acidophilus La-5. Cheeses 
manufactured solely with La-5 presented populations above 1 x 106 CFU/g, reaching 1 x 107 
CFU/g on the 14th day of storage. 
The Argentinean fresh cheese is a soft rindless cheese with a ripening period of 12 days at  
5 ºC before its commercial distribution. This cheese presents the following physicochemical 
characteristics: pH 5.29, moisture 58% (w/w), fat 12% (w/w), proteins 23% (w/w), salt 0.9% 
(w/w), ashes 3.4% (w/w), dry matter 40.8% (w/w) and calcium 0.6% (w/w). This product has 
proven to be an adequate vehicle for probiotic bacteria during storage and until 
consumption. It offers offer a certain degree of protection of the viability of bacteria during 
the in vitro simulation of gastric transit (Vinderola et al., 2000). 
Kasimoglu et al. (2004) have shown that L. acidophilus strain can be used for the manufacture 
of probiotic Turkish white cheese. The final numbers of L. acidophilus were greater than the 
minimum (107 cfu g-1) required to make health benefits claims. Furthermore, L. acidophilus 
can be used to enhance flavor, texture, and a produce a high level of proteolysis. Moreover, 
probiotic cheese which was vacuum packed following salting was shown to be more 
acceptable than the corresponding cheese stored in brine following salting. Therefore, 
vacuum packaging is the preferred means for storing probiotic Turkish white cheeses. 
6. Concluding remarks and future trends 
In conclusion, probiotic microorganisms, including bacteria and yeasts, are attracting a 
growing interest due to their promising physiological effects as well as the value they add to 
probiotic-containing food products. There is a growing body of evidence that probiotics may 
play a beneficial role in human health (Ouwehand et al., 2002; Collado et al., 2009). 
Established effects in humans include alleviation of symptoms linked to lactose intolerance 
or to irritable bowel syndrome. They also include reduced diarrhea associated with 
antibiotic treatment, rotavirus or traveler’s diseases. It should be emphasized that the 
beneficial properties of probiotic microorganisms are highly dependent on the strains, 
which means that each strain or product requires demonstration of the specific effects in 
vivo. The possibility of using certain probiotics to modulate the immune system, particularly 
at the mucosal level (O'Flaherty et al., 2010) is the most promising application. In this 
respect, promising healing effects were obtained using the probiotic mixture VSL#3 on 
ulcerative colitis patients (Miele et al., 2009; Huynh et al., 2009; Ng et al., 2010). These 
clinical studies, which still need to be confirmed by larger studies, strongly suggest that 
selected strains of probiotics may help in treating the bowel diseases which constitute a 
growing health concern in developing countries. Clearly, animal studies suggest other 
promising probiotic effects incuding inflammatory diseases, allergies and associated 
asthma, and colorectal cancer. These applications open exciting avenues that must be 
investigated at both molecular and clinical levels. 
Understanding the impact of ingested bacteria on health, as well as the impact of gut 
microbiota perturbation (dysbiosis) on emerging diseases, including immune disorders and 
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cancer remains a great challenge. In developed countries, gut microbiota have evolved with 
a reduced diversity of bacterial species (Yatsunenko et al., 2012). This is particularly true in 
Crohn’s disease patients (Manichanh et al., 2006), who lack immunomodulatory anti-
inflammatory bacteria, including Faecalibacterium prausnitzii (Sokol et al., 2008). A similar 
reduced diversity was also described in the case of colorectal cancer, (Chen et al., 2012) 
confirming the involvement of dysbiosis in digestive cancers (Azcarate-Peril et al., 2011). 
The composition of gut microbiota is linked to long term dietary patterns (Wu et al., 2011). 
This suggests that ingested bacteria can participate in the prevention and/or treatment of 
emerging diseases. This hypothesis has been reinforced by recent epidemiological studies 
which show that raw milk prevents the onset of allergy and asthma in children (Loss et al., 
2011; Waser et al., 2007; Braun-Fahrlander et al., 2011). The authors suggested a protective 
immunomodulatory role of raw milk bacteria (Braun-Fahrlander et al., 2011).  
Most interestingly, bacterial species used as dairy starters display promising properties in 
this field. For example, immunomodulatory anti-inflammatory properties were described in 
certain strains of Propionibacterium freudenreichii (Foligné et al., 2010; Deutsch et al., 2012), 
Streptococcus thermophilus (Ogita et al., 2011), Lactobacillus delbrueckii subsp. bulgaricus and 
subsp. lactis (Santos-Rocha et al., 2012), as well as Lactobacillus helveticus (Guglielmetti et al., 
2010). Modulation of colon cancer cell growth was also reported in vitro and/or in animal 
models for P. freudenreichii (Cousin et al., 2010; Lan et al., 2008), when the cells were exposed 
to yogurt containing S. thermophilus and L. bulgaricus (Narushima et al., 2010; Perdigon et al., 
2002)  and L. helveticus (de Moreno et al., 2010). Future trends may thus include the 
development of specific fermented dairy products designed for specific population. These 
could use bacteria strains and employ both technological capabilities and probiotic potential 
to affect immune system modulation, gut physiology and cancer cells. 
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